| FSELX | KTCIX | FSELX / KTCIX | |
| Total Expense Ratio | 0.62 | 0.68 | 91% |
| Annual Report Gross Expense Ratio | 0.62 | 0.68 | 91% |
| Fund Existence | 40 years | 23 years | - |
| Gain YTD | 30.565 | 22.061 | 139% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 1000000 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 26.3B | 2.17B | 1,212% |
| Annual Yield % from dividends | 0.00 | 0.00 | - |
| Returns for 1 year | 25.14 | 18.23 | 138% |
| Returns for 3 years | 209.85 | 105.82 | 198% |
| Returns for 5 years | 205.79 | 57.13 | 360% |
| Returns for 10 years | 457.61 | 201.17 | 227% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| BRWCX | 27.65 | 0.24 | +0.88% |
| MFS Blended Research Growth Eq C | |||
| RTNCX | 14.06 | 0.05 | +0.36% |
| Russell Inv Tax-Managed Intl Eq C | |||
| IJPTX | 12.64 | N/A | N/A |
| VY® JPMorgan Emerging Markets Equity S2 | |||
| PHPSX | 23.30 | N/A | N/A |
| ProFunds Pharmaceuticals UltraSector Svc | |||
| EVSIX | 27.59 | N/A | N/A |
| Allspring Disciplined US Core Inst | |||